- Home
- / BioVie
BioVie
Stock Price
$2.6
2024-10-29
Market Capitalization
$23.1 M
2024-10-29
BioVie Summary
Company Summary
- Overview
- BioVie (formerly knows as NanoAntibiotics) is a therapeutical company developing approaches targeting ascites due to liver cirrhosis. The company's developed therapy BIV201 is based on a drug that is not yet available in the US but is approved in about 50 countries to treat related complications of liver cirrhosis.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Santa Monica, CA, US | view all locations
- Cybersecurity rating
- Sectors
Table of Contents
Key People
Jonathan Adams, Executive Vice President, Liver Disease Program
Joseph M. Palumbo, Chief Medical Officer
Clarence Ahlem, Executive Vice President, Neuroscience Product Development
LocationsView all
1 location detected
Santa Monica, CA HQ
United States
2120 Colorado Ave #230
BioVie Financials
Summary Financials
- Net income (Q3, 2026)
- ($5.3M)
- Cash (Q3, 2026)
- $13.1M
- EBIT (Q3, 2026)
- ($5.4M)
- Enterprise value
- $10.3M